Comparison of conventional medicine, TCM treatment, and combination of both conventional medicine and TCM treatment for patients with chronic obstructive pulmonary disease: study protocol of a randomized comparative effectiveness research trial

Jian-Sheng Li, Yang Xie, Su-Yun Li, Xue-Qing Yu, Jian-Sheng Li, Yang Xie, Su-Yun Li, Xue-Qing Yu

Abstract

Background: Chronic obstructive pulmonary disease (COPD) affects millions worldwide. Although many therapies exist and are being developed to relieve symptoms and reduce mortality, few data are available to understand which of the therapeutic alternatives is the most cost-effective for COPD patients in everyday clinical practice, especially for traditional Chinese medicine (TCM). Comparative effectiveness research can help patients, clinicians, and decision-makers make best informed treatment decisions where such evidence was previously lacking. This study aims to compare the effectiveness and economic evaluation of three treatments: (1) conventional Western medicine; (2) TCM treatments, which have been evaluated and have certain effect; and (3) a combination of both conventional Western medicine and TCM treatments, and then determine which treatment is the most suitable for COPD patients.

Methods/design: A multicenter, pragmatic, randomized, controlled trial is adopted. A total of 360 patients will be recruited and randomly assigned to one of the three treatments group, with 120 in each group. Patients in the conventional Western medicine group will be given Salbutamol, Formoterol, Salmeterol/fluticasone, respectively, according to the guidelines. For the TCM group, patients will be given Bufei granule, Bu-Fei Jian-Pi granule, Bu-Fei Yi-Shen granule, and Yi-Qi Zi-Shen granule based on their corresponding TCM syndrome patterns, respectively. For the combination of conventional medicine and TCM treatments group, patients will be given a combination of conventional Western medicine and TCM granules. Treatments in each group are recognized as a whole comprehensive intervention. After the 26-week treatment, another 26 weeks will be followed up. The outcome measures including the frequency and duration of acute exacerbations, lung function, dyspnea, exercise capacity, quality of life, and economic evaluation will be assessed.

Discussion: It is hypothesized that each of the three treatments will have beneficial effects in reducing the frequency and duration of acute exacerbations, improving exercise capacity and psychosocial function of COPD patients. In addition, the combination of conventional medicine and TCM treatments may be most suitable for COPD patients with better effectiveness and economic evaluation.

Trial registration: ClinicalTrials.gov NCT01836016.

Figures

Figure 1
Figure 1
Technical route of this comparative effectiveness research study.

References

    1. Raherison C, Girodet PO. Epidemiology of COPD. Eur Respir Rev. 2009;18:213–221. doi: 10.1183/09059180.00003609.
    1. Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Zhou Y, Liu S, Wang X, Wang D, Lu J, Zheng J, Ran P. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176:753–760. doi: 10.1164/rccm.200612-1749OC.
    1. Lin HH, Murray M, Cohen T, Colijn C, Ezzati M. Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. Lancet. 2008;372:1473–1483. doi: 10.1016/S0140-6736(08)61345-8.
    1. National Heart Lung and Blood Institute. Morbidity and Mortality: 2009 Chart Book on Cardiovascular, Lung, and Blood Diseases. [ ]
    1. Heffner JE, Mularski RA, Calverley PM. COPD performance measures: missing opportunities for improving care. Chest. 2010;137:1181–1189. doi: 10.1378/chest.09-2306.
    1. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;16:2359–2367.
    1. Krishnan JA, Mularski RA. Acting on comparative effectiveness research in COPD. JAMA. 2010;303:2409–2410. doi: 10.1001/jama.2010.807.
    1. Lieu TA, Au D, Krishnan JA, Moss M, Selker H, Harabin A, Taggart V, Connors A. Comparative effectiveness research in lung disease and sleep disorders: recommendations from the National Heart, Lung, and Blood Institute workshop. Am J Respir Crit Care Med. 2011;184:848–856. doi: 10.1164/rccm.201104-0634WS.
    1. Krishnan JA, Lindenauer PK, Au DH, Carson SS, Lee TA, McBurnie MA, Naureckas ET, Vollmer WM, Mularski RA. Stakeholder priorities for comparative effectiveness research in chronic obstructive pulmonary disease: a workshop report. Am J Respir Crit Care Med. 2013;187:320–326. doi: 10.1164/rccm.201206-0994WS.
    1. Federal Coordinating Council for CER Report to the President and Congress. [ ]
    1. Feudtner C, Schreiner M, Lantos JD. Risks (and benefits) in comparative effectiveness research trials. N Engl J Med. 2013;369:892–894. doi: 10.1056/NEJMp1309322.
    1. Lauer MS, Collins FS. Using science to improve the nation’s health system: NIH’s commitment to comparative effectiveness research. JAMA. 2010;303:2182–2183. doi: 10.1001/jama.2010.726.
    1. Li JS, Li SY, Yu XQ, Xie Y, Wang MH, Li ZG, Zhang NZ, Shao SJ, Zhang YJ, Zhu L, Guo LX, Bai YP, Wang YF. Bu-Fei Yi-Shen granule combined with acupoint sticking therapy in patients with stable chronic obstructive pulmonary disease: a randomized, double-blind, double-dummy, active-controlled, 4-center study. J Ethnopharmacol. 2012;141:584–591. doi: 10.1016/j.jep.2011.08.060.
    1. Li SY, Li JS, Wang MH, Xie Y, Yu XQ, Sun ZK, Ma LJ, Zhang W, Zhang HL, Cao F, Pan YC. Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study. BMC Complement Altern Med. 2012;12:197. doi: 10.1186/1472-6882-12-197.
    1. Global Initiative for Chronic Obstructive Lung Disease Global strategy for diagnosis, management, and prevention of COPD (GOLD) [ ]
    1. COPD Study Group of Chinese Society of Respiratory Disease. Treatment guidelines of chronic obstructive pulmonary disease (Revised 2013) Zhong Hua Jie He Yu Hu Xi Za Zhi. 2013;36:1–10.
    1. Li JS, Li SY, Wang ZW, Yu XQ, Wang MH, Wang YY. Syndrome diagnostic criteria of TCM of chronic obstructive pulmonary disease (2011 edition) Zhong Yi Za Zhi. 2012;53:177–178.
    1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary the ATS/ERS position paper. Eur Respir J. 2004;23:932–946. doi: 10.1183/09031936.04.00014304.
    1. Mahler DA, Well CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93:580–586. doi: 10.1378/chest.93.3.580.
    1. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648–654. doi: 10.1183/09031936.00102509.
    1. Rutten-van Mölken MP, Goossens LM. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics. 2012;30:271–302. doi: 10.2165/11589270-000000000-00000.
    1. Campbell JD, Zerzan J, Garrison LP Jr, Libby AM. Comparative-effectiveness research to aid population decision making by relating clinical outcomes and quality-adjusted life years. Clin Ther. 2013;35:364–370. doi: 10.1016/j.clinthera.2013.02.011.
    1. Schneeweiss S, Seeger JD, Jackson JW, Smith SR. Methods for comparative effectiveness research/patient-centered outcomes research: from efficacy to effectiveness. J Clin Epidemiol. 2013;66:S1–S4. doi: 10.1016/j.jclinepi.2013.05.012.
    1. Chalkidou K, Tunis S, Whicher D, Fowler R, Zwarenstein M. The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research. Clin Trials. 2012;9:436–446. doi: 10.1177/1740774512450097.
    1. Hahn OM, Schilsky RL. Randomized controlled trials and comparative effectiveness research. J Clin Oncol. 2012;30:4194–4201. doi: 10.1200/JCO.2012.42.2352.
    1. Li JS, Wang ZW, Yu XQ, Wang MH, Li SY. Clinical efficacy and safety of TCM for COPD at stable phase: a systematic review. Liaoning Zhong Yi Za Zhi. 2010;37:229–232. 235.
    1. Li JS, Xie Y, Yu XQ, Li SY, Shao SJ, Guo LX, Zhu L, Zhang YJ, Zhang HL, Cao F. An evaluation of self-efficacy and satisfaction with the effectiveness of Bu-Fei Yi-Shen Granule combined with acupoint sticking therapy in patients with chronic obstructive pulmonary disease. Eur J Integr Med. 2013;5:313–325. doi: 10.1016/j.eujim.2013.03.005.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir